Cara Therapeutics, INC 10-Q quarterly reports

Tvardi Therapeutics reported continued operating losses and a substantial accumulated deficit in its Q2 2026 10-Q filing, though it highlighted positive clinical data for its TTI-109 candidate and recent capital raises.

Tvardi Therapeutics reported a wider net loss for Q1 2026 driven by increased R&D spending, while cash reserves remain a concern.

Tvardi Therapeutics reports Q3 2025 results, revealing the TTI-101 IPF Phase 2 trial did not meet its goals, alongside ongoing net losses and substantial doubt about its ability to continue as a going concern, despite a recent merger.

Tvardi Therapeutics, Inc. reported a Q2 2025 net income driven by a non-cash gain, but faces substantial doubt about its ability to continue as a going concern amid increased cash burn and rising public company costs.

Tvardi Therapeutics, formerly Cara Therapeutics, reports its first quarterly results post-merger, highlighting financial details and strategic shifts.

Cara Therapeutics is exploring strategic alternatives to maximize shareholder value after discontinuing its notalgia paresthetica clinical program due to lack of efficacy.

Cara Therapeutics discontinues its notalgia paresthetica program and initiates a strategic review to maximize shareholder value, following disappointing clinical trial results.

Cara Therapeutics reported its first quarter 2024 financial results, highlighting a strategic shift towards the development of oral difelikefalin for notalgia paresthetica (NP) and a workforce reduction.